Investors Asset Management of Georgia Inc. GA ADV Sells 1,640 Shares of Johnson & Johnson (NYSE:JNJ)

Investors Asset Management of Georgia Inc. GA ADV reduced its stake in Johnson & Johnson (NYSE:JNJ) by 11.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,437 shares of the company’s stock after selling 1,640 shares during the period. Johnson & Johnson accounts for 1.0% of Investors Asset Management of Georgia Inc. GA ADV’s holdings, making the stock its 20th biggest holding. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Johnson & Johnson were worth $1,609,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of JNJ. Virtus ETF Advisers LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $26,000. Crewe Advisors LLC lifted its position in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares during the period. Permanens Capital L.P. lifted its position in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares during the period. Finally, Personal Wealth Partners purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $73,000. Institutional investors and hedge funds own 72.05% of the company’s stock.

NYSE:JNJ opened at $127.70 on Friday. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The firm has a 50 day moving average of $130.45 and a 200 day moving average of $134.76. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $359.38 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 2.30 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 8.65 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.98%. Johnson & Johnson’s payout ratio is 46.45%.

Several equities research analysts have recently weighed in on JNJ shares. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target for the company in a research report on Thursday. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $151.18.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Monthly Dividend Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.